Prognostic benefit of comprehensive genomic profiling in clinical practice remains uncertain

The overall survival of patients who received genomically matched therapy was not significantly longer than that of patients receiving treatment only other than genomically matched therapy in the breast invasive ductal carcinoma (A), colorectal adenocarcinoma (B), and pancreatic adenocarcinoma (C) c...

Descripción completa

Detalles Bibliográficos
Autor principal: Ikegami, Masachika
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2023
Materias:
LETTERS TO THE EDITOR
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10323084/
https://www.ncbi.nlm.nih.gov/pubmed/37121885
http://dx.doi.org/10.1111/cas.15826
_version_ 1785068891718811648
author Ikegami, Masachika
author_facet Ikegami, Masachika
author_sort Ikegami, Masachika
collection PubMed
description The overall survival of patients who received genomically matched therapy was not significantly longer than that of patients receiving treatment only other than genomically matched therapy in the breast invasive ductal carcinoma (A), colorectal adenocarcinoma (B), and pancreatic adenocarcinoma (C) cohorts.[Image: see text]
format Online
Article
Text
id pubmed-10323084
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-103230842023-07-07 Prognostic benefit of comprehensive genomic profiling in clinical practice remains uncertain Ikegami, Masachika Cancer Sci LETTERS TO THE EDITOR The overall survival of patients who received genomically matched therapy was not significantly longer than that of patients receiving treatment only other than genomically matched therapy in the breast invasive ductal carcinoma (A), colorectal adenocarcinoma (B), and pancreatic adenocarcinoma (C) cohorts.[Image: see text] John Wiley and Sons Inc. 2023-04-30 /pmc/articles/PMC10323084/ /pubmed/37121885 http://dx.doi.org/10.1111/cas.15826 Text en © 2023 The Author. Cancer Science published by John Wiley & Sons Australia, Ltd on behalf of Japanese Cancer Association. https://creativecommons.org/licenses/by-nc/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.
spellingShingle LETTERS TO THE EDITOR
Ikegami, Masachika
Prognostic benefit of comprehensive genomic profiling in clinical practice remains uncertain
title Prognostic benefit of comprehensive genomic profiling in clinical practice remains uncertain
title_full Prognostic benefit of comprehensive genomic profiling in clinical practice remains uncertain
title_fullStr Prognostic benefit of comprehensive genomic profiling in clinical practice remains uncertain
title_full_unstemmed Prognostic benefit of comprehensive genomic profiling in clinical practice remains uncertain
title_short Prognostic benefit of comprehensive genomic profiling in clinical practice remains uncertain
title_sort prognostic benefit of comprehensive genomic profiling in clinical practice remains uncertain
topic LETTERS TO THE EDITOR
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10323084/
https://www.ncbi.nlm.nih.gov/pubmed/37121885
http://dx.doi.org/10.1111/cas.15826
work_keys_str_mv AT ikegamimasachika prognosticbenefitofcomprehensivegenomicprofilinginclinicalpracticeremainsuncertain

Ejemplares similares